This is a routine vesting disclosure with no trading signal. Monitor for any subsequent open-market sales by Soriot, which would be separately reported. No immediate action warranted.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $183.91entry
- T+1 · 6mo ago +0.42%α +1.07% · $184.68
- T+5 · 6mo ago +1.74%α +0.12% · $187.11
- T+20 · 5mo ago −3.61%α −5.80% · $177.27
- T+60 · 3mo ago −14.01%α −18.59% · $158.14
Price Chart
How similar events traded
Executive Summary
AstraZeneca filed a 6-K reporting the vesting of a performance share award to CEO Pascal Soriot on 14 May 2026. The award, granted in 2021 under the AstraZeneca Performance Share Plan, vested at 88% of target after a three-year performance period and two-year holding period, with 18,359 shares acquired for nil consideration. This is a routine executive compensation disclosure with no material financial or operational impact.
Key Facts
- CEO Pascal Soriot received 18,359 ordinary shares upon vesting of a 2021 AZPSP award on 14 May 2026.
- The award vested at 88% of target after a three-year performance period and two-year holding period.
- Shares were acquired for nil consideration; 13,766 pence per share was the fair market value for tax purposes.
- The filing is a routine PDMR shareholding disclosure with no new business or financial information.
Financial Impact
No material financial impact. The vesting involves 18,359 shares at a tax reference value of 13,766 pence each, but no cash consideration changed hands.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005049 |
| Document: 0001654954-26-005049-index-headers.html | 0001654954-26-005049 |
| Document: 0001654954-26-005049-index.html | 0001654954-26-005049 |
| Document: 0001654954-26-005049.txt | 0001654954-26-005049 |
Track record
77 reports on AZN
19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers